|
See related Tasigna Hard cap information |
|
|
|
Manufacturer |
Novartis |
|
Distributor |
Zuellig |
|
Contents |
Nilotinib HCl |
|
Indications |
Chronic & accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (CML) in adults resistant to or intolerant to at least 1 prior therapy including imatinib.
Click to view Tasigna detailed prescribing infomation |
|
Dosage |
400 mg bid 12 hrly.
Click to view Tasigna detailed prescribing infomation |
|
Overdosage |
View Tasigna overdosage for action to be taken in the event of an overdose. |
|
Administration |
Should be taken on an empty stomach (Avoid food at least 2 hr before & at least 1 hr after a dose. Swallow whole, do not chew/crush. Avoid grapefruit products.). |
|
Contraindications |
[Click for Tasigna detailed prescribing infomation] |
|
Warnings |
For additional cautionary notes to warn of the potential risk of using the medicine... click to view Tasigna detailed prescribing infomation |
|
Special Precautions |
Do not use in patient w/ hypokalemia, hypomagnesemia or long QT syndrome. Patients taking antiarrhythmics or drugs that may lead to QT prolongation, cumulative high-dose anthracycline therapy. Myelosuppression, hepatic impairment, cardiac disease or significant cardiac risk factors, history of pancreatitis. Galactose intolerance, severe lactase deficiency, glucose-galactose malabsorption (Tasigna contains lactose). Monitor QTc, CBC. Pregnancy, lactation.
Click to view Tasigna detailed prescribing infomation |
|
Adverse Drug Reactions |
Headache, nausea, constipation, diarrhoea, vomiting, abdominal pain, rash, pruritus, alopecia, myalgia, arthralgia, muscle spasms, bone pain, fatigue, asthenia, peripheral oedema, anorexia.
View ADR Monitoring Form |
|
Drug Interactions |
Strong CYP3A4 inhibitors (eg ketoconazole, itraconazole, voriconazole, ritonavir, clarithromycin, telithromycin), CYP3A4 inducers (eg phenytoin, rifampicin, carbamazepine, phenobarb, St John's wort), CYP2C8, CYP2C9 & CYP2D6 substrates, antiarrhythmics (eg amiodarone, disopyramide, procainamide, quinidine, sotalol), drugs that prolong QT interval (eg chloroquine, halofantrine, clarithromycin, haloperidol, methadone, moxifloxacin, bepridil, pimozide).
View more drug interactions with Tasigna |
|
Pregnancy Category (US FDA) |
Category D: There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective). |
|
Description |
View Tasigna description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Tasigna mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Tasigna Hard capsule |
|
Tasigna 200 mg x 28's |
 |
|
|
|
Manufacturer: |
Novartis |
|
Distributor: |
Zuellig
|
|
|
|
